IL-37 (human) (recombinant protein) (His)

Specifications / Handling

More Information
Product Details
Synonyms	Interleukin-1 Family Member 7; IL-1F7; FIL1 zeta; IL-1X; Interleukin-1 Homolog 4; IL-1H4; Interleukin-1 zeta; IL-1 zeta; IL-1RP1; IL1F7; FIL1Z, IL1H4, IL1RP1
Product Type	Protein
Properties
Source/Host	E. coli
Sequence	Human IL-37 (aa 1-218) is fused at the C-terminus to a His-tag.
Crossreactivity	Human
MW	~30kDa (SDS-PAGE)
Purity	≥95% (SDS-PAGE)
Endotoxin Content	<0.05EU/μg purified protein (LAL test; Lonza).
Concentration	0.1mg/ml after reconstitution.
Reconstitution	Reconstitute with 100μl sterile water.
Formulation	Lyophilized. Contains PBS.
Other Product Data	UniProt link Q9NZH6: IL-37 (human)
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability	Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

IL-37 (IL-1F7; IL-1H4) is an IL-1 family member that is expressed only in certain types of human organs and cells such as heart, thymus, testis, kidney, mononuclear cells (PBMCs) and dendritic cells. IL-37 is an inhibitor of innate immunity with anti-inflammatory properties. It binds to the interleukin-18 receptor (IL-18R) and its co-receptor SIGIRR. IL-37 is secreted as a full-length and as a processed form starting from amino acid Val46. It plays an important role as a link between innate and adaptive immunity and acts as an inhibitor of autoimmune diseases and tumor growth. IL-37 also inhibited Lipopolysaccharide (LPS)-induced immunological reaction and LPS-induced osteoclast formation and bone resorption.

Product References

Interleukin-37 ameliorates myocardial ischemia/reperfusion injury in mice: B. Wu, et al.; Clin. Exp. Immunol. 176, 438 (2014)
The evaluation of plasma and leukocytic IL-37 expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI: X. Wang, et al.; Med. Inflamm. 2015, ID626934 (2015)
The protective effect of Interleukin-37 on vascular calcification and atherosclerosis in apolipoprotein: M. Chai, et al.; J. Interferon Cytok. Res. 35, 530 (2015)
Interleukin-37 Relieves Allergic Inflammation in a House Dust Mite Allergic Rhinitis Murine Model: D.H. Kim, et al.; Iran J. Allergy Asthma Immunol. 16, 404 (2017)
Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice: Q. Ji, et al.; Nature Sci. Rep. 7, 3310 (2017)
IL-37 expression is downregulated in lesional psoriasis skin: K. Ronholt, et al.; Immunohorizons 4, 754 (2020)

Call	+41 61 926 6040
Fax	+41 61 926 6049

IL-37 (human) (rec.) (His)